Cinacalcet Hydrochloride Patent Expiration
Cinacalcet Hydrochloride is Used for treating hyperparathyroidism and hypercalcemia by decreasing parathyroid hormone levels and modulating its secretion. It was first introduced by Amgen Inc
Cinacalcet Hydrochloride Patents
Given below is the list of patents protecting Cinacalcet Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sensipar | US7829595 | Rapid dissolution formulation of a calcium receptor-active compound | Sep 22, 2026 | Amgen |
| Sensipar | US9375405 | Rapid dissolution formulation of a calcium receptor-active compound | Sep 22, 2026 | Amgen |
| Sensipar | US6011068 | Calcium receptor-active molecules |
Mar 08, 2018
(Expired) | Amgen |
| Sensipar | US6031003 | Calcium receptor-active molecules |
Dec 14, 2016
(Expired) | Amgen |
| Sensipar | US6313146 | Calcium receptor-active molecules |
Dec 14, 2016
(Expired) | Amgen |
| Sensipar | US6211244 | Calcium receptor-active compounds |
Oct 23, 2015
(Expired) | Amgen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cinacalcet Hydrochloride's patents.
Latest Legal Activities on Cinacalcet Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Cinacalcet Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2023 | US9375405 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2022 | US7829595 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2019 | US9375405 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2018 | US7829595 |
| Post Issue Communication - Certificate of Correction | 13 Feb, 2018 | US9375405 |
| Patent Issue Date Used in PTA Calculation Critical
| 28 Jun, 2016 | US9375405 |
| Recordation of Patent Grant Mailed Critical
| 28 Jun, 2016 | US9375405 |
| Issue Notification Mailed Critical
| 08 Jun, 2016 | US9375405 |
| Dispatch to FDC | 25 May, 2016 | US9375405 |
| Application Is Considered Ready for Issue Critical
| 25 May, 2016 | US9375405 |
Cinacalcet Hydrochloride's Family Patents
